An oncological view on the blood-testis barrier.

The function of the blood-testis barrier is to protect germ cells from harmful influences; thus, it also impedes the delivery of chemotherapeutic drugs to the testis. The barrier has three components: first, a physicochemical barrier consisting of continuous capillaries, Sertoli cells in the tubular wall, connected together with narrow tight junctions, and a myoid-cell layer around the seminiferous tubule. Second, an efflux-pump barrier that contains P-glycoprotein in the luminal capillary endothelium and on the myoid-cell layer; and multidrug-resistance associated protein 1 located basolaterally on Sertoli cells. Third, an immunological barrier, consisting of Fas ligand on Sertoli cells. Inhibition of P-glycoprotein function offers the opportunity to increase the delivery of cytotoxic drugs to the testis. In the future, visualisation of function in the blood-testis barrier may also be helpful to identify groups of patients in whom testis conservation is safe or to select drugs that are less harmful to fertility.

[1]  G. Perry,et al.  Barrier properties of testis microvessels. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[2]  V. Dixit,et al.  Death receptors: signaling and modulation. , 1998, Science.

[3]  R. Advani,et al.  Treatment of Refractory and Relapsed Acute Myelogenous Leukemia With Combination Chemotherapy Plus the Multidrug Resistance Modulator PSC 833 (Valspodar) , 1999 .

[4]  D. Altman,et al.  Testis conservation studies in germ cell cancer justified by improved primary chemotherapy response and reduced delay, 1978-1994. , 1996, British journal of urology.

[5]  L. Dunkel,et al.  Fas regulates germ cell apoptosis in the human testis in vitro. , 1999, American journal of physiology. Endocrinology and metabolism.

[6]  A. Sartorelli,et al.  Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[7]  C Tondini,et al.  Diffuse large-cell lymphoma of the testis. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  F. Vaylet,et al.  Pulmonary Metastasis Secondary to Burned-Out Testicular Tumor , 2000, Respiration.

[9]  R. Oliver,et al.  Current opinion in germ cell cancer 2000. , 2000, Current opinion in oncology.

[10]  J. Beijnen,et al.  Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient Mice. , 1996, Journal of the National Cancer Institute.

[11]  J. Wijnholds,et al.  Multidrug Resistance Protein 1 Protects the Oropharyngeal Mucosal Layer and the Testicular Tubules against Drug-induced Damage , 1998, The Journal of experimental medicine.

[12]  G. Masera,et al.  Relapse after first cessation of therapy in childhood acute lymphoblastic leukemia: a 10-year follow-up study. Italian Association of Pediatric Hematology-Oncology (AIEOP). , 1995, Medical and pediatric oncology.

[13]  A. Covelli Modulation of multidrug resistance (MDR) in hematological malignancies. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  S. Nagata,et al.  Testicular FasL is expressed by sperm cells , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[15]  J. Kerr 1 Functional cytology of the human testis , 1992 .

[16]  A. Duncan,et al.  Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. , 1992, Science.

[17]  W Vaalburg,et al.  A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier. , 1999, Cancer research.

[18]  M. Kool,et al.  Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. , 1997, Cancer research.

[19]  M C Willingham,et al.  Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[20]  T. Tsuruo,et al.  Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16. , 1988, Cancer research.

[21]  D. Bellgrau,et al.  A role for CD95 ligand in preventing graft rejection , 1995, Nature.

[22]  F. Baas,et al.  Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines. , 1993, Cancer research.

[23]  M. Kool,et al.  Expression of human MRP6, a homologue of the multidrug resistance protein gene MRP1, in tissues and cancer cells. , 1999, Cancer research.

[24]  T. Flotte,et al.  Immunohistochemical characterization of seminoma and its inflammatory cell infiltrate. , 1987, Human pathology.

[25]  R. Elton,et al.  Immunocompetent cells in human testis in health and disease. , 1987, Fertility and sterility.

[26]  J. Pont,et al.  Fertility after chemotherapy for testicular germ cell cancer. , 1997, Fertility and sterility.

[27]  H. Kluin-Nelemans,et al.  Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC study. , 2001, Journal of the National Cancer Institute.

[28]  J. Cox,et al.  Testicular lymphoma: late relapses and poor outcome despite doxorubicin-based therapy. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  N. Skakkebaek,et al.  Dose-dependent impairment of testicular function in patients treated with cisplatin-based chemotherapy for germ cell cancer. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  D. Dearnaley,et al.  Fertility after chemotherapy for testicular germ cell cancers. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  B. Sikic,et al.  Clinical trials of modulation of multidrug resistance pharmacokinetic and pharmacodynamic considerations , 1993, Cancer.

[32]  M. Melamed,et al.  Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[33]  P. Borst,et al.  Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. , 1995, The Journal of clinical investigation.

[34]  T. Tsuruo,et al.  Distribution of multidrug resistance-associated P-glycoprotein in normal and neoplastic human tissue , 1990 .

[35]  W. Whitmore,et al.  Effect of treatment on fertility and sexual function in males with metastatic nonseminomatous germ cell tumors of testis , 1985, American journal of clinical oncology.

[36]  E. Bruera,et al.  Results of a phase III, double-blind, placebo-controlled trial of megestrol acetate modulation of P-glycoprotein-mediated drug resistance in the first-line management of small-cell lung carcinoma. , 1998, British Journal of Cancer.

[37]  W Vaalburg,et al.  Complete in vivo reversal of P‐glycoprotein pump function in the blood‐brain barrier visualized with positron emission tomography , 1998, British journal of pharmacology.

[38]  M. Wiley,et al.  Developing nervous tissue induces formation of blood-brain barrier characteristics in invading endothelial cells: a study using quail--chick transplantation chimeras. , 1981, Developmental biology.

[39]  G. W. Gross,et al.  Metastatic seminoma with regression of testicular primary: ultrasonographic detection. , 1986, The Journal of urology.

[40]  U. Brinkmann,et al.  Frequency of C3435T polymorphism of MDR1 gene in African people , 2001, The Lancet.

[41]  S. Byers,et al.  The blood‐testis barrier and sertoli cell junctions: Structural considerations , 1992, Microscopy research and technique.

[42]  J. H. Beijnen,et al.  Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs , 1994, Cell.

[43]  G. Peters,et al.  MRP3, an organic anion transporter able to transport anti-cancer drugs. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[44]  R. Sharpe,et al.  Response of the seminiferous epithelium of the rat testis to withdrawal of androgen: evidence for direct effect upon intercellular spaces associated with Sertoli cell junctional complexes , 1993, Cell and Tissue Research.

[45]  R. Kramer,et al.  Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. , 1993, Cancer research.

[46]  C. Higgins,et al.  ABC transporters: from microorganisms to man. , 1992, Annual review of cell biology.

[47]  D. Fawcett,et al.  The blood-testis barrier in the rat and the physiological compartmentation of the seminiferous epithelium. , 1970, Biology of reproduction.

[48]  R. Evers,et al.  Basolateral localization and export activity of the human multidrug resistance-associated protein in polarized pig kidney cells. , 1996, The Journal of clinical investigation.

[49]  Wan Ariffin Bin Abdullah,et al.  Med Pediatr Oncol , 1999 .

[50]  U. Brinkmann,et al.  Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[51]  I. Bechmann,et al.  FasL (CD95L, Apo1L) is expressed in the normal rat and human brain: Evidence for the existence of an immunological brain barrier , 1999, Glia.

[52]  P. Kuchel,et al.  Mechanism of action of P-glycoprotein in relation to passive membrane permeation. , 1999, International review of cytology.

[53]  A. Renshaw,et al.  Burned-out primary testicular cancer: sonographic and pathological characteristics. , 1996, The Journal of urology.

[54]  L. Russell,et al.  Observations on the inter-relationships of Sertoli cells at the level of the blood- testis barrier: evidence for formation and resorption of Sertoli-Sertoli tubulobulbar complexes during the spermatogenic cycle of the rat. , 1979, The American journal of anatomy.

[55]  R. Bergmann,et al.  Mrp1 Multidrug Resistance‐Associated Protein and P‐Glycoprotein Expression in Rat Brain Microvessel Endothelial Cells , 1998, Journal of neurochemistry.

[56]  H. Hoekstra,et al.  Cisplatin-based chemotherapy changes the incidence of bilateral testicular cancer , 1997, Annals of Surgical Oncology.

[57]  D. Miller,et al.  Expression of multidrug resistance-associated protein (MRP) in brain microvessel endothelial cells. , 1998, Biochemical and biophysical research communications.

[58]  G. Mead,et al.  Orchiectomy after chemotherapy in patients with metastatic testicular cancer. Is it indicated? , 1995, Cancer.

[59]  A. Abbas,et al.  Functional roles of Fas and Bcl-2-regulated apoptosis of T lymphocytes. , 1998, Journal of immunology.

[60]  N. Rucci,et al.  Fas and Fas ligand expression in fetal and adult human testis with normal or deranged spermatogenesis. , 2000, The Journal of clinical endocrinology and metabolism.

[61]  D. Keppler,et al.  Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. , 1999, Biochimica et biophysica acta.

[62]  W Vaalburg,et al.  The blood-brain barrier and oncology: new insights into function and modulation. , 2000, Cancer treatment reviews.

[63]  N. Yamamoto,et al.  Induction of blood–brain barrier properties in immortalized bovine brain endothelial cells by astrocytic factors , 1999, Neuroscience Research.

[64]  R L Juliano,et al.  A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. , 1976, Biochimica et biophysica acta.

[65]  M. Kool,et al.  Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. , 1998, The Journal of clinical investigation.

[66]  S. Thorgeirsson,et al.  Multidrug resistance gene family and chemical carcinogens. , 1991, Pharmacology & therapeutics.

[67]  D D Breimer,et al.  Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier. , 2000, The Journal of clinical investigation.

[68]  K. Liu,et al.  In situ observation of inflammatory cell-tumor cell interaction in human seminomas (germinomas): light, electron microscopic, and immunohistochemical study. , 1992, Human pathology.

[69]  W. Kamps,et al.  Intensive treatment of children with acute lymphoblastic leukemia according to ALL-BFM-86 without cranial radiotherapy: results of Dutch Childhood Leukemia Study Group Protocol ALL-7 (1988-1991). , 1999, Blood.

[70]  C. Beglinger,et al.  Evidence for Different ABC-Transporters in Caco-2 Cells Modulating Drug Uptake , 1999, Pharmaceutical Research.

[71]  K. Boekelheide,et al.  THE FAS SYSTEM IS A KEY REGULATOR OF GERM CELL APOPTOSIS IN THE TESTIS , 1997 .